SYSTEMATHICS
8.3.2022 15:02:13 CET | Business Wire | Press release
Systemathics , the trading automation technology specialist, has now integrated its Ganymede product with ICE DataVault.
Built as cloud native, Ganymede is a fully managed platform, continuously updated with high-quality, curated, and cross validated data. Ganymede is purpose built for the financial data markets ever increasing data volumes, allowing clients to query against large data sets, including tick-by-tick, sampled, daily, corporate actions, ESG and reference data. Packed with a broad range of analytics, the solution is optimized for fast response times, supports full order book natively and allows fine grained/customizable trade and quote conditions mapping and filtering.
ICE DataVault is a comprehensive, cloud-accessible archive of historical tick data from the ICE Consolidated Feed and is designed to capture tick-by-tick data for trades and quotes across multiple assets, including equities, derivatives, fixed income, foreign exchange, cryptocurrencies, money markets, energy and ETFs, with history spanning up to 10+ years. ICE DataVault provides users with granular, high quality financial information with full depth-of-market coverage that can allow for strategy backtesting, historical analysis, trade surveillance and compliance use cases.
David Denis, CTO at Systemathics, said, “Ganymede users will now be able to access ICE’s deep tick-by-tick data set captured from ICE Consolidated Feed. Systemathics’ user friendly, robust and automated tools will help its customers capture, normalize, store and analyze massive data sets that are critical for investment decisions and compliance requirements.”
Mark Heckert, Chief Product Officer, Fixed Income and Data Services, at ICE said, “Across global markets, a competitive edge demands the application of big data sets. Yet the management of that data, including processing, collecting and storage, can be challenging and costly. Our work with Ganymede can allow clients to externalize the complexities of corralling their data in the cloud infrastructure and provide them with ways to use and integrate that data into actual business processes.”
ICE DataVault is part of Intercontinental Exchange (NYSE: ICE).
About Systemathics
Systemathics is a French fintech founded in 2008 developing its innovative products with the highest quality standards 100% in France. Our main mission is to provide global investors with a complete end-to-end solution to systematize alpha generation in a robust way. From data pre and post trade analysis, back-testing, risk assessment and signal generation to day-to-day execution in production and everything in between.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220301005844/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
SOLUM and Simbe Expand European Collaboration to Advance Intelligent Store Operations5.3.2026 08:00:00 CET | Press release
SOLUM (KOSPI: 248070) and Simbe announced the expansion of their strategic collaboration to further integrate autonomous store intelligence with SOLUM’s Newton Electronic Shelf Label (ESL) infrastructure across Europe. The collaboration was highlighted at EuroShop, where Simbe’s Store Intelligence™ platform was demonstrated live at the SOLUM booth. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260304620371/en/ SOLUM and Simbe announced the expansion of their strategic collaboration to further integrate autonomous store intelligence with SOLUM’s Newton Electronic Shelf Label (ESL) infrastructure across Europe. (Image: SOLUM) Simbe recently introduced Tally 4.0, the next generation of their autonomous shelf-scanning robot, reflecting the company’s continued evolution in retail shelf digitization, incorporating extended runtime, enhanced edge computing, and advanced vision capabilities. Designed to deliver deeper shelf coverag
Mosaic Clinical Technologies Announces FDA Breakthrough Device Designation for Cognita’s Generative AI Model for Radiology5.3.2026 08:00:00 CET | Press release
Breakthrough designation means Cognita™ will engage in prioritized interaction with FDA regarding clearance of device designed to help solve the radiology capacity bottleneck Mosaic Clinical Technologies™, a wholly-owned subsidiary of Radiology Partners, is pleased to announce that Cognita™, its AI business unit developing generative vision-language models (VLMs) for radiology, has received U.S. Food and Drug Administration (FDA) Breakthrough Device Designation for Cognita Chest X-Ray (CXR)™1 across multiple critical indications. Cognita CXR is an industry-first generative vision-language model designed to assist radiologists in the interpretation of chest X-rays and is the first radiology generative AI model, and one of very few radiology AI solutions, to be granted this designation2. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260304633206/en/ Cognita™ operates as the AI business unit of Mosaic Clinical Technologies™, a
Cielo Advances Resilient Remote Connectivity for Its Nationwide Payment Terminal Fleet With Thales5.3.2026 08:00:00 CET | Press release
Cielo, one of Brazil’s leading payment service providers, is piloting remote connectivity management for its point-of-sale (POS) terminals across the country, in partnership with Thales. By deploying Thales’s eSIM connectivity management platform based on the latest GSMA SGP.32 IoT standard, Cielo is accelerating its transition from manual, on-site SIM management to fully remote, secure and resilient connectivity. For Cielo, connectivity is mission critical. When payment terminals lose network access, transactions stop. To strengthen operational resilience and enhance merchant experience, Cielo is modernizing its connectivity architecture across its terminal fleet. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260304089321/en/ Cielo advances resilient remote connectivity for its nationwide payment terminal fleet with Thales. Using Thales’s eSIM technology as part of this strategy, Cielo can remotely switch mobile network op
GAIA and Daiichi Sankyo Europe Enter Exclusive Partnership to Launch Next-Generation Digital Therapeutic for Cardiovascular Care in Europe.5.3.2026 08:00:00 CET | Press release
GAIA, the pioneer in evidence-based digital therapeutics and Daiichi Sankyo Europe, today announced an exclusive strategic partnership to commercialize lipodia upon regulatory approval1. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260224658973/en/ Dr. Mario Weiss, Founder & CEO of GAIA AG This digital therapeutic is designed to support adults living with hypercholesterolemia. The comprehensive collaboration brings together GAIA’s long-standing expertise in developing clinically validated non-pharmacological interventions with Daiichi Sankyo’s highly scientific experience in cardiovascular risk management and health. Together, the partners - both members of the German Association of Research-Based Pharmaceutical Companies (vfa) - aim to address a persistent gap in chronic care: leveraging digital technologies to make a difference in patients’ lives by supporting sustainable, long-term behaviour change. Expanding Cardiovasc
Galderma Delivers Record 2025 Results With Net Sales of 5.207 Billion USD, up 17.7% at Constant Currency1, and Core EBITDA2 of 1.211 billion USD, Growing 18.9% at Constant Currency5.3.2026 07:00:00 CET | Press release
Ad hoc announcement pursuant to Art. 53 LR Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, today announced its financial results for the full year 2025. Record net sales of 5,207 million USD, surpassing 5 billion USD in a year for the first time and representing 17.7% year-on-year growth on a constant currency1 basis, primarily driven by volume. Broad-based net sales growth, growing double-digits in both International markets and the U.S. Outperforming the market in each product category, with strong net sales growth in Injectable Aesthetics (11.5%), Dermatological Skincare (9.3%) and Therapeutic Dermatology (50.2%), all year-on-year at constant currency. Strong launch momentum across future growth drivers, including Nemluvio® (nemolizumab) delivering 452 million USD in net sales; Relfydess™ (RelabotulinumtoxinA) outperforming expectations in 17 International markets; Sculptra® gaining significant market share in its first year in China; and continued new produ
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom